Understanding how growth hormone affects insulin-producing cells in women with gestational diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the response of beta-cells in the pancreas to growth hormone in individuals with a history of gestational diabetes. Conducted at the University of Missouri, the research focuses on understanding the relationship between growth hormone and the risk factors for developing gestational diabetes and type 2 diabetes. Participants will be categorized into two groups: those with a history of gestational diabetes and a control group without such a history. The study will analyze how these groups differ in their beta-cell function and insulin regulation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Singleton, full term pregnancy within the past 5 years
* Body mass index ≥18.5 kg/m2 and \<45.0 kg/m2

Group specific inclusion criteria:

* Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy
* Control Group: no history of gestational diabetes

Exclusion Criteria:

* Pregnant, planning to become pregnant during the study, or breastfeeding
* Current diagnosis or history of type 1 or type 2 diabetes
* Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
* History of bariatric surgery
* Known, uncontrolled hypothyroidism
* History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
* Current cancer or cancer that has been in remission less than 5 years
* First degree relative with diabetes diagnosis
* Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
* Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
* Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
* Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

Where it's running

• University of Missouri School of Medicine
  Columbia, Missouri, United States Recruiting

Study contacts

• Principal investigator: Bettina Mittendorfer, PhD — University of Missouri-Columbia
• Study coordinator: Amanda Heider
• Email: ahmc4@health.missouri.edu
• Phone: 573-884-6852

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Peking University Weifang Birth Cohort

  This project will follow pregnant women in Weifang and their children to see if pre-pregnancy and prenatal exposures affect maternal and child health up to age 18.

  Recruiting Peking University · Beijing, Beijing Municipality · NCT06234332

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.